Focused On-demand Library for Zinc finger protein Gfi-1

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We employ our advanced, specialised process to create targeted libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.

Several key aspects differentiate our library:

Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

partner

Reaxense

upacc

Q99684

UPID:

GFI1_HUMAN

Alternative names:

Growth factor independent protein 1; Zinc finger protein 163

Alternative UPACC:

Q99684; Q8N564

Background:

Zinc finger protein Gfi-1, also known as Growth factor independent protein 1 and Zinc finger protein 163, plays a pivotal role in hematopoiesis. It acts as a transcription repressor, essential for the development of multiple blood cell lines. Gfi-1's ability to bind specific promoter regions and form complexes that suppress genes implicated in blood cell development underscores its significance in regulating neutrophil differentiation and lymphoid cell proliferation.

Therapeutic significance:

Gfi-1's involvement in severe congenital Neutropenia and chronic idiopathic Neutropenia of adults highlights its therapeutic potential. Understanding the role of Zinc finger protein Gfi-1 could open doors to potential therapeutic strategies for these hematopoietic disorders, offering hope for targeted treatments that could alleviate or even cure these conditions.